talaporfin sodium + temozolomide

Talaporfin sodium + temozolomide is a combination therapy used primarily in the treatment of glioma and glioblastoma. Talaporfin sodium (also known as NPe6 or mono-L-aspartyl chlorine e6) is a photosensitizer used in photodynamic therapy (PDT), which induces selective cell death in neoplastic tissue when activated by specific wavelengths of light. Temozolomide is an oral alkylating agent that damages tumor DNA, leading to cell death. The combination has been shown to enhance apoptotic cell death in glioma cells compared to either agent alone, with evidence suggesting that concomitant administration increases intracellular accumulation of talaporfin sodium and reactive oxygen species production, thereby potentiating the cytotoxic effect. This regimen has been studied for its potential to improve local tumor control and progression-free survival in patients with malignant brain tumors[1][3][6].

Other names

NPe6 + temozolomidemono-L-aspartyl chlorine e6 + temozolomide